Healthcare ❯ Pharmaceuticals

Biotechnology

Drug Development Clinical Trials Multiple Sclerosis Treatments Industry Analysis Obesity Treatments Biopharmaceuticals Vaccines Combination Treatments Company Performance Genomics Cardiovascular Treatments Product Sales Drug Discovery Rare Diseases Diabetes Treatments Investment Opportunities Stock Performance Cancer Treatment Oncology Corporate Strategies Market Trends Regeneron Inflammatory Diseases Moderna Mental Health

Krystal Biotech Posts Strong Q4 as VYJUVEK Hits $107 Million, Pivots 2026 Growth to Ex‑U.S. Markets

Management now looks to ex‑U.S. launches to drive 2026 growth.

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline